Agenus (AGEN) News Today $2.98 -0.12 (-3.72%) Closing price 05/6/2025 03:59 PM EasternExtended Trading$2.98 +0.00 (+0.17%) As of 05/6/2025 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Critical Survey: Agenus (NASDAQ:AGEN) versus Tectonic Therapeutic (NASDAQ:TECX)May 5 at 2:15 AM | americanbankingnews.comB. Riley Financial Inc. Makes New $2.07 Million Investment in Agenus Inc. (NASDAQ:AGEN)B. Riley Financial Inc. purchased a new stake in shares of Agenus Inc. (NASDAQ:AGEN - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 756,956 shares of the biotechnologyMay 3, 2025 | marketbeat.comHC Wainwright Reiterates "Neutral" Rating for Agenus (NASDAQ:AGEN)May 3, 2025 | americanbankingnews.comAgenus (NASDAQ:AGEN) Given Neutral Rating at HC WainwrightHC Wainwright reaffirmed a "neutral" rating on shares of Agenus in a report on Wednesday.May 2, 2025 | marketbeat.comAgenus (AGEN) Expected to Announce Quarterly Earnings on TuesdayAgenus (NASDAQ:AGEN) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-agenus-inc-stock/)May 1, 2025 | marketbeat.comAgenus to Provide Corporate Update and First Quarter 2025 Financial ReportApril 29, 2025 | finance.yahoo.comAgenus’ BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACRApril 28, 2025 | finance.yahoo.comAgenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACRApril 28, 2025 | businesswire.comResearch Analysts Issue Forecasts for Agenus Q1 EarningsAgenus Inc. (NASDAQ:AGEN - Free Report) - Analysts at B. Riley lifted their Q1 2025 earnings per share estimates for shares of Agenus in a note issued to investors on Monday, April 21st. B. Riley analyst M. Mamtani now forecasts that the biotechnology company will post earnings of ($1.82) per shaApril 26, 2025 | marketbeat.comAgenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025 | AGEN Stock NewsApril 25, 2025 | gurufocus.comAgenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025April 25, 2025 | gurufocus.comAgenus’ BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025April 25, 2025 | finance.yahoo.comAgenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025April 25, 2025 | businesswire.comB. Riley Estimates Agenus' FY2029 Earnings (NASDAQ:AGEN)Agenus Inc. (NASDAQ:AGEN - Free Report) - B. Riley raised their FY2029 earnings estimates for shares of Agenus in a research report issued to clients and investors on Monday, April 21st. B. Riley analyst M. Mamtani now forecasts that the biotechnology company will earn $0.38 per share for the yeaApril 25, 2025 | marketbeat.comAgenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025April 23, 2025 | businesswire.comAgenus price target lowered to $8 from $11 at B. RileyApril 22, 2025 | markets.businessinsider.comAgenus Inc. (NASDAQ:AGEN) Receives Consensus Recommendation of "Hold" from AnalystsAgenus Inc. (NASDAQ:AGEN - Get Free Report) has received a consensus recommendation of "Hold" from the six brokerages that are currently covering the stock, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to tApril 21, 2025 | marketbeat.com231,663 Shares in Agenus Inc. (NASDAQ:AGEN) Acquired by Gilead Sciences Inc.Gilead Sciences Inc. purchased a new stake in Agenus Inc. (NASDAQ:AGEN - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 231,663 shares of the biotechnology company's stock, valued at approximately $635,000. AApril 20, 2025 | marketbeat.comAgenus Inc. (AGEN) to Present Key Cancer Research at AACR MeetingApril 17, 2025 | gurufocus.comAgenus to Present New BOT/BAL Data in Two Presentations at AACR 2025March 25, 2025 | businesswire.comAgenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment ...March 19, 2025 | gurufocus.comAgenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment InnovationMarch 19, 2025 | businesswire.comRobert W. Baird Cuts Agenus (NASDAQ:AGEN) Price Target to $3.00Robert W. Baird decreased their price target on shares of Agenus from $6.00 to $3.00 and set a "neutral" rating for the company in a report on Wednesday.March 13, 2025 | marketbeat.comAgenus (NASDAQ:AGEN) Given "Neutral" Rating at HC WainwrightHC Wainwright reissued a "neutral" rating on shares of Agenus in a research note on Wednesday.March 13, 2025 | marketbeat.comQ4 2024 Agenus Inc Earnings CallMarch 13, 2025 | uk.finance.yahoo.comAgenus price target lowered to $3 from $6 at BairdMarch 12, 2025 | markets.businessinsider.comAgenus Inc. (NASDAQ:AGEN) Q4 2024 Earnings Call TranscriptMarch 12, 2025 | msn.comAgenus (NASDAQ:AGEN) Releases Earnings Results, Beats Estimates By $0.32 EPSAgenus (NASDAQ:AGEN - Get Free Report) announced its earnings results on Tuesday. The biotechnology company reported ($2.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.36) by $0.32.March 12, 2025 | marketbeat.comWilliam Blair Sticks to Its Hold Rating for Agenus (AGEN)March 11, 2025 | markets.businessinsider.comAgenus reports Q4 EPS ($2.04), consensus ($2.54)March 11, 2025 | markets.businessinsider.comAgenus (AGEN) Q4 2024 Earnings Call TranscriptMarch 11, 2025 | msn.comAgenus stock falls after revenue missMarch 11, 2025 | msn.comAgenus Inc. (AGEN) Q4 2024 Earnings Call TranscriptMarch 11, 2025 | seekingalpha.comAgenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL ProgramMarch 11, 2025 | financialpost.comAgenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL ProgramMarch 11, 2025 | businesswire.comAgenus Q4 2024 Earnings PreviewMarch 10, 2025 | seekingalpha.comAgenus (AGEN) to Release Earnings on TuesdayAgenus (NASDAQ:AGEN) will be releasing earnings before the market opens on Tuesday, March 11, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=669789)March 4, 2025 | marketbeat.comAgenus Inc. (NASDAQ:AGEN) Given Average Rating of "Hold" by BrokeragesAgenus Inc. (NASDAQ:AGEN - Get Free Report) has been given an average rating of "Hold" by the six analysts that are currently covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company.March 1, 2025 | marketbeat.comAgenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed PublicationsFebruary 26, 2025 | finance.yahoo.comAgenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed PublicationsFebruary 26, 2025 | businesswire.comAgenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor ConferenceFebruary 25, 2025 | businesswire.comAgenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial ReportFebruary 25, 2025 | finance.yahoo.comAgenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial ReportFebruary 25, 2025 | businesswire.comCORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO ...February 24, 2025 | gurufocus.comCORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual MeetingFebruary 23, 2025 | businesswire.comAgenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual MeetingFebruary 12, 2025 | finance.yahoo.comAgenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual MeetingFebruary 12, 2025 | businesswire.comIncyte terminates license agreement with AgenusFebruary 11, 2025 | markets.businessinsider.comKuehn Law Encourages Investors of Agenus Inc. to Contact Law FirmFebruary 4, 2025 | markets.businessinsider.comAgenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of "Hold" by AnalystsAgenus Inc. (NASDAQ:AGEN - Get Free Report) has received a consensus rating of "Hold" from the six research firms that are currently covering the firm, MarketBeat reports. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average twelve-mFebruary 4, 2025 | marketbeat.com Get Agenus News Delivered to You Automatically Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address AGEN Media Mentions By Week AGEN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AGEN News Sentiment▼0.160.69▲Average Medical News Sentiment AGEN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AGEN Articles This Week▼66▲AGEN Articles Average Week Get Agenus News Delivered to You Automatically Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies XOMA News Vanda Pharmaceuticals News Emergent BioSolutions News Codexis News Lexicon Pharmaceuticals News Sangamo Therapeutics News Ironwood Pharmaceuticals News Achieve Life Sciences News Dominari News Fortress Biotech News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AGEN) was last updated on 5/7/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agenus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agenus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AGEN Stock Free AGEN Stock Alerts